Ozmosi | Narazaciclib Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Narazaciclib

Pronounced as: nuh-RAH-zuh-sih-klib

Alternative Names: Narazaciclib, on-123300, on 123300, on123300, hx-301, hx 301, hx301
Clinical Status: Active
Latest Update: 2026-01-26
Latest Update Note: News Article

Product Description

novel multi-kinase inhibitor; Notably, ON 123300's ability to target multiple kinase pathways that are overexpressed in cancer may allow for single-agent efficacy and better tolerability compared to existing treatment regimens. (Sourced from: https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-announces-initial-dosing-first-patient-us)

Mechanisms of Action: CDK4 Inhibitor, CDK6 Inhibitor, ARK5 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hangzhou Hansi Biopharmaceutical Co., Ltd. / Wuhan Hanxiong Biotechnology Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Narazaciclib

Countries in Clinic: China

Active Clinical Trial Count: 4

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Onconova presented P0 Mantle-Cell Lymphoma results on 2023-12-11 for Narazaciclib
  • Clinical Outcomes Reported - Onconova presented P0 Oncology Solid Tumor Unspecified results on 2023-12-08 for Narazaciclib

Highest Development Phases

Phase 2: Glioblastoma|Glioma

Phase 1: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05731934

HX301-I-01

P1

Completed

Oncology Solid Tumor Unspecified

2024-01-12

12%

2024-07-23

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT06703255

Grade III and IV

P2

Recruiting

Glioma

2026-12-31

12%

2025-01-16

Primary Endpoints|Start Date|Treatments|Trial Status

CTR20200063

CTR20200063

P1

Completed

Oncology Solid Tumor Unspecified

2024-07-03

2026-02-10

Primary Completion Date|Study Completion Date|Treatments|Trial Status

CTR20244225

CTR20244225

P2

Recruiting

Glioblastoma

None

2025-04-29

Patient Enrollment|Start Date|Treatments|Trial Status